The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 13, 2012

Filed:

May. 15, 2008
Applicants:

Vadivel Ganapathy, Martinez, GA (US);

Puttur D. Prasad, Martinez, GA (US);

Muthusamy Thangaraju, Evans, GA (US);

Gail Cresci, Augusta, GA (US);

Inventors:

Vadivel Ganapathy, Martinez, GA (US);

Puttur D. Prasad, Martinez, GA (US);

Muthusamy Thangaraju, Evans, GA (US);

Gail Cresci, Augusta, GA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/04 (2006.01); A61K 31/70 (2006.01);
U.S. Cl.
CPC ...
Abstract

Pharmaceutical compositions containing an effective amount of a ligand for GPR109 to decrease intracellular cAMP levels of a subject in combination with an effective amount of a DNA methyl transferase inhibito to reduce or inhibit downregulation of GPR109 in the intestinal epithelial cells of the subject relative to a control are provided. It has been discovered that ligands for GPR109 can be used to treat one or more symptoms of cancer, inflammatory disorders, and diarrhea. Representative CPR109 ligands include, but are not limited to butyrate, β-hydroxybutyrate, nicotinic acid, acifran, and octanoate. Suitable DNA methyl transferase inhibitors include 5-azacytidine, 5-aza-2'-deoxytidine, 1-β-D-arabinfarnosyl-5-azacytosine and dihydro-5-azacytidine. Typically, the compositions are formulated to achieve a GPR109 ligand serum blood level of about 1 to about 1000 μM. The compositions are useful for the treatment of one or more symptoms of cancer. Preferred cancers that can be treated using the disclosed compositions include, but are not limited to colon cancer, breast cancer and leukemia. Methods for treating cancer, inflammatory disorders, and diarrhea are also provided.


Find Patent Forward Citations

Loading…